From: High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
Toxicity
Grade
Gastrointestinal
Genitourinary
Grade 5
0%
Grade 4
Grade 3
17 (4.8%)
Grade 2
6 (1.7%)
58 (16.5%)
Grade 1
55 (15.7%)
169 (48.1%)